Who We Are

Advaccine is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline based on in-house developed technology platforms.

Driven by innovative science and our research and development efforts, our competitive pipeline consists of potential first-in-class key assets developed to address diseases caused by SARS-CoV-2, RSV and HBV, which are diseases with huge unmet medical needs.

We are also developing vaccine candidates in preclinical stage covering oncology, as well as neoantigen therapeutic vaccines and tumor-associated antigen therapeutic vaccines. To deliver our transformed vaccines to society, we have embedded the commitment in all aspect of our work.